IGHE and asthma: Plenty of real-world studies have shown that long-term, continuous use of Omalizumab, an anti-IgE antibody, can greatly reduce exacerbations, asthma related emergency visits and hospital admissions, OCS maintenance doses and fraction exhaled nitric oxide levels, as well as improve asthma control, lung function and quality of life in adult and pediatric patients with severe allergic asthma (SAA) [4,5,6,7,8,9,10,11,12,13,14].